Acadia is trailblazing breakthroughs in neuroscience to elevate life.
Acadia aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
For more information, follow us on LinkedIn.
News
February 24, 2021
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Company Information
Publication Spotlight
Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).
Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.